Treatment of childhood kaposiform hemangioendothelioma with sirolimus
Pediatric Blood & Cancer2010Vol. 55(7), pp. 1396–1398
Citations Over TimeTop 10% of 2010 papers
Abstract
Sirolimus (Rapamune), a mammalian target of Rapamycin (mTOR) inhibitor, which has been used extensively in children following solid organ transplantation, has been demonstrated to have anti-angiogenic activity in pre-clinical models. Limited experience suggests that it may have application to the treatment of vascular lesions. We describe our experience with a 1-year-old female with a kaposiform hemangioendothelioma and Kasabach-Merritt phenomenon who had rapid and dramatic response to sirolimus (0.1 mg/kg/day). This case provides further rationale for clinical trials of sirolimus in the treatment of vascular lesions.
Related Papers
- → Treatment of Lymphatic Malformations with the mTOR Inhibitor Sirolimus: A Systematic Review(2018)168 cited
- → Antitumor activity of nab-sirolimus versus mTOR inhibitors temsirolimus, sirolimus, and everolimus in A549 NSCLC xenografts.(2024)2 cited
- → POS-794 Conversion to sirolimus in kidney transplant patients: the main indications(2022)
- → MTOR INHIBITOR SIROLIMUS IN THE TREATMENT OF THERAPY RESISTANT INFANTILE STAGE III HEMIMANDIBULAR AV-MALFORMATION(2016)
- → The combination of sirolimus plus an mTOR inhibitor has potential for the treatment of patients with recurrent glioma,(2006)